Menlo Therapeutics Inc. said on July 18 that it completed a $50m Series C round led by venBio with participation from Novo Holdings A/S, Rock Springs Capital, Aisling Capital and Bay City Capital as well as the company's Series A and B investors, including Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital. Menlo Park, Calif.-based Menlo Therapeutics is developing the NK-1 receptor antagonist serlopitant for chronic pruritus, or itching, associated with various conditions. It will use the Series C proceeds to start two Phase III clinical trials in prurigo nodularis pruritus starting in the first half of 2018 (Phase II results were reported earlier this year), to conduct an ongoing Phase II trial in atopic dermatitis, and to prepare for the start of Phase II studies in psoriasis pruritus and refractory chronic cough during the second half of 2017. (Also see "Pipeline Watch: Phase III Readouts For Guselkumab, Volanesorsen And Dupilumab" - Scrip, 13 March, 2017.)

Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter

More from Financing

More from Business